[Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
Banaschewski
T
T
Döpfner
M
M
Rothenberger
A
A
Steinhausen
H -C
H-
D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003692:Delayed-Action Preparations; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects; D011613:Psychotherapy; D016896:Treatment Outcome
D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride